Trial Profile

Safety and Tolerability of S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARM 210 (Primary)
Indications Congenital structural myopathies
Focus Adverse reactions
Acronyms RYR1-RM
Sponsors ARMGO Pharma

Most Recent Events

18 Apr 2024 Status changed from active, no longer recruiting to completed.
30 Jan 2024 According to ARMGO Pharma media release, the data from this study published in the peer reviewed Journal eClinicalMedicine, part of the Lancet family of publications.
29 Jan 2024 Results ARMGO Pharma published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com